30-Apr-2024
No headlines found.
U.S. FDA Renews DILIsym Software Licenses for 7th Year
Business Wire (Thu, 4-Apr 8:30 AM ET)
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Business Wire (Wed, 3-Apr 4:34 PM ET)
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
Business Wire (Wed, 20-Mar 4:06 PM ET)
Business Wire (Wed, 13-Mar 8:30 AM ET)
Simulations Plus and the University of Bath Awarded New FDA Grant
Business Wire (Tue, 5-Mar 8:30 AM ET)
Simulations Plus Extends Collaboration with Major Toxicology Research Agency
Business Wire (Thu, 15-Feb 8:30 AM ET)
Simulations Plus Launches Corporate Development Initiative
Business Wire (Tue, 13-Feb 9:15 AM ET)
Simulations Plus to Participate in Upcoming Healthcare Conferences
Business Wire (Tue, 6-Feb 8:30 AM ET)
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
Simulations Plus trades on the NASDAQ stock market under the symbol SLP.
As of April 30, 2024, SLP stock price declined to $45.35 with 62,136 million shares trading.
SLP has a beta of 1.32, meaning it tends to be more sensitive to market movements. SLP has a correlation of 0.16 to the broad based SPY ETF.
SLP has a market cap of $905.45 million. This is considered a Small Cap stock.
Last quarter Simulations Plus reported $18 million in Revenue and $.20 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.01.
In the last 3 years, SLP stock traded as high as $67.59 and as low as $32.58.
The top ETF exchange traded funds that SLP belongs to (by Net Assets): IJR, VTI, IWM, VXF, SPSM.
SLP has underperformed the market in the last year with a price return of +9.2% while the SPY ETF gained +22.3%. However, in the short term, SLP had mixed performance relative to the market. It has outperformed in the last 3 months, returning +14.3% vs +2.5% return in SPY. But in the last 2 weeks, SLP shares have been beat by the market, returning -0.6% compared to an SPY return of -0.5%.
SLP support price is $44.28 and resistance is $46.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLP stock will trade within this expected range on the day.